Scholarlink

<p>Bronchopulmonary dysplasia (BPD) is a serious complication of extreme prematurity and has few treatment options. The postnatal use of steroids to prevent BPD remains controversial, but prophylactic low-dose hydrocortisone (HC) has been shown to improve survival without BPD. However, an increased risk of late-onset sepsis (LOS) was also reported in extremely preterm neonates exposed to prophylactic HC treatment. Because its causal link remains unclear, our objective was to assess the effect of prophylactic HC exposure on LOS risk, adjusted for perinatal risk factors of LOS. We re-analyzed the PREMILOC trial to investigate the postnatal factors influencing the incidence of LOS occurring after day 3 from baseline conditions and to evaluate the potential interaction produced by prophylactic HC exposure. We used three different statistical models (poisson, Cox regression, competing risks) to test the effect of HC on LOS occurrence. LOS was reported in 64/264 (24%) and 77/255 (30%) in the placebo and HC groups, respectively (<i>P</i> = 0.12). A decreasing risk of LOS was observed with increasing gestational age (<i>P</i> &lt; 0.001), vaginal delivery (<i>P</i> = 0.005), and supplemental corticosteroids given after a 10-day treatment with prophylactic HC but before the LOS (<i>P</i> &lt; 0.001). A trend of higher risk of LOS was noted in infants exposed to perinatal asphyxia (<i>P</i> = 0.065). Adjusted for these covariates, we found a non-significant association between HC exposure and risk of LOS (relative risk, 1.041 (95% CI, 0.738 to 1.471]), <i>P</i> = 0.817). Using a survival competing risk analysis, we confirmed the lack of significant effect of HC on LOS (hazard risk ratio, 1.105 [95% CI, 0.787 to 1.552], <i>P</i> = 0.560), while competing death was significantly reduced by the treatment (hazard risk ratio, 0.427 [95% CI, 0.259 to 0.707], <i>P</i> &lt; 0.001).</p><p><i>Conclusion</i>: The effect of prophylactic HC compared with placebo on LOS is summarized by a risk ratio varying within the interval [0.90–1.10] and this effect was never significant.</p><p><i>Trial registration</i>: EudraCT number 2007–002041-20, ClinicalTrials.gov number NCT00623740.</p><p><Table Float="No" ID="Taba"> <tgroup cols="1"> <colspec align="left" colname="c1" colnum="1" /> <tbody> <row> <entry align="left" colname="c1"> <p><b>What is Known:</b></p> <p>•&#xa0;<i>Prophylactic hydrocortisone improves survival without bronchopulmonary dysplasia in extremely preterm neonates.</i></p> <p>•&#xa0;<i>It increases the risk of late-onset sepsis in the most immature infants.</i></p> <p>•&#xa0;<i>Causality remains unclear.</i></p> </entry> </row> <row> <entry align="left" colname="c1"> <p><b>What is New:</b></p> <p>• <i>A lower risk of late-onset sepsis was observed with higher gestational age at birth, vaginal delivery, and, more surprisingly, with supplemental corticosteroids administration after day 10.</i></p> <p>• <i>Competing survival by Fine and Gray analysis suggests that death was reduced by prophylactic hydrocortisone, without a significant effect of treatment on the risk of late-onset sepsis.</i></p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm

  • 期刊论文

  • 发表日期：

    2025年6月14日

查看全文
  • Olivier Baud,
  • Philippe Lehert,
  • Valérie Biran,
  • Aline Rideau Batista-Novais,
  • Caroline Farnoux,
  • Sophie Soudée,
  • Laure Maury,
  • Michèle Granier,
  • Florence Lebail,
  • Duksha Ramful,
  • Sylvain Samperiz,
  • Alain Beuchée,
  • Karine Guimard,
  • Fatima El Moussawi,
  • Pascal Boileau,
  • Florence Castela,
  • Claire Nicaise,
  • Renaud Vialet,
  • Pierre Andrini,
  • Thierry Debillon,
  • Véronique Zupan-Simunek,
  • Hasinirina Razafimahefa,
  • Anne Coursol,
  • Saïd Merbouche,
  • Pascal Bolot,
  • Jean-Marc Kana,
  • Julie Guichoux,
  • Olivier Brissaud,
  • Gérard Thiriez,
  • Olivier Schulze,
  • Mickael Pomedio,
  • Patrice Morville,
  • Thierry Blanc,
  • Stéphane Marret,
  • Bernard Guillois,
  • Cénéric Alexandre,
  • Stéphane Le Bouëdec,
  • Bertrand Leboucher,
  • Umberto Simeoni,
  • Valérie Lacroze,
  • Pierre Kuhn,
  • Stéphanie Litzler-Renaud,
  • Elodie Zana-Taïeb,
  • Pierre-Henri Jarreau,
  • Sylvain Renolleau,
  • Virginie Meau-Petit,
  • Gilles Cambonie,
  • Corinne Alberti,
  • Aurélie Bourmaud

摘要

Bronchopulmonary dysplasia (BPD) is a serious complication of extreme prematurity and has few treatment options. The postnatal use of steroids to prevent BPD remains controversial, but prophylactic low-dose hydrocortisone (HC) has been shown to improve survival without BPD. However, an increased risk of late-onset sepsis (LOS) was also reported in extremely preterm neonates exposed to prophylactic HC treatment. Because its causal link remains unclear, our objective was to assess the effect of prophylactic HC exposure on LOS risk, adjusted for perinatal risk factors of LOS. We re-analyzed the PREMILOC trial to investigate the postnatal factors influencing the incidence of LOS occurring after day 3 from baseline conditions and to evaluate the potential interaction produced by prophylactic HC exposure. We used three different statistical models (poisson, Cox regression, competing risks) to test the effect of HC on LOS occurrence. LOS was reported in 64/264 (24%) and 77/255 (30%) in the placebo and HC groups, respectively (P = 0.12). A decreasing risk of LOS was observed with increasing gestational age (P < 0.001), vaginal delivery (P = 0.005), and supplemental corticosteroids given after a 10-day treatment with prophylactic HC but before the LOS (P < 0.001). A trend of higher risk of LOS was noted in infants exposed to perinatal asphyxia (P = 0.065). Adjusted for these covariates, we found a non-significant association between HC exposure and risk of LOS (relative risk, 1.041 (95% CI, 0.738 to 1.471]), P = 0.817). Using a survival competing risk analysis, we confirmed the lack of significant effect of HC on LOS (hazard risk ratio, 1.105 [95% CI, 0.787 to 1.552], P = 0.560), while competing death was significantly reduced by the treatment (hazard risk ratio, 0.427 [95% CI, 0.259 to 0.707], P < 0.001).

Conclusion: The effect of prophylactic HC compared with placebo on LOS is summarized by a risk ratio varying within the interval [0.90–1.10] and this effect was never significant.

Trial registration: EudraCT number 2007–002041-20, ClinicalTrials.gov number NCT00623740.

What is Known:

• Prophylactic hydrocortisone improves survival without bronchopulmonary dysplasia in extremely preterm neonates.

• It increases the risk of late-onset sepsis in the most immature infants.

• Causality remains unclear.

What is New:

• A lower risk of late-onset sepsis was observed with higher gestational age at birth, vaginal delivery, and, more surprisingly, with supplemental corticosteroids administration after day 10.

• Competing survival by Fine and Gray analysis suggests that death was reduced by prophylactic hydrocortisone, without a significant effect of treatment on the risk of late-onset sepsis.